scholarly journals 1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S790-S790
Author(s):  
Mary Francine P Chua ◽  
Syeda Sara Nida ◽  
Jerry Lawhorn ◽  
Vidya Sundareshan
Keyword(s):  
Susceptibility Testing ◽  
Test Method ◽  
The Novel ◽  
Local Hospital ◽  
Vancomycin Resistant Enterococci ◽  
Vancomycin Resistant ◽  
Human Infections ◽  
Susceptibility Profiles ◽  
Tetracycline Group

Abstract Background Vancomycin-resistant Enterococci (VRE) are nosocomial pathogens that cause significant morbidity and mortality especially among patients with chronic medical conditions, critical illness and prolonged hospitalizations. Majority of human infections are caused by two species— E. faecium and E. faecalis, and which can acquire resistance to ampicillin, aminoglycosides, and vancomycin. Our aim was to study the susceptibility profile of the VRE strains to the tetracycline group of antibiotics on isolates collected from our local hospital. Older tetracyclines and their novel derivatives are included in this study. Methods Eighty preserved isolates of VRE were tested against five tetracyclines, i.e. doxycycline, minocycline, tigecycline, eravacycline and omadacycline. Antimicrobial susceptibility testing was performed using the E-test method in accordance to CLSI guidelines. Isolates were then classified as either susceptible, intermediately susceptible or resistant based on established breakpoints. Results Eighty isolates (54 VRE. faecium and 26 VRE. faecalis) were included in the study. Out of 54 E. faecium isolates, 52 (96.3%) were susceptible to tigecycline, 15 (27.8%) were susceptible to minocycline, 14 (25.9%) were susceptible to doxycycline, 42 (77.8 %) were susceptible to omadacycline, and 52 (96.3%) were susceptible to eravacycline. Out of 26 E. faecalis isolates, 26 (100%) were susceptible to tigecycline, 2 (7.6%) were susceptible to minocycline, 2 (7.6%) were susceptible to doxycycline, 2 (7.6%) were susceptible to omadacycline, and 25 (96.15%) were susceptible to eravacycline. Conclusion Tigecycline and eravacycline exhibited better in vitro antimicrobial activity against vancomycin-resistant E. faecium and E. faecalis when compared to doxycycline and minocycline. Omadacycline showed a relatively favorable susceptibility profile for E. faecium, but less favorable for E. faecalis. Results of this study will be useful to incorporate in the local antibiogram and will guide antimicrobial stewardship efforts. These findings will not only add to existing knowledge on susceptibility profiles of the novel tetracyclines, i.e. eravacycline and omadacycline, but also on their applicability in the clinical setting. Disclosures All Authors: No reported disclosures

scholarly journals In Vitro and In Vivo Activities of DA-7867, a New Oxazolidinone, against Aerobic Gram-Positive Bacteria

2005 ◽  
Vol 49 (6) ◽  
pp. 2498-2500 ◽  
Author(s):  
Eun Jeong Yoon ◽  
Yeong Woo Jo ◽  
Sung Hak Choi ◽  
Tae Ho Lee ◽  
Jae Keol Rhee ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Gram Positive ◽  
Methicillin Resistant ◽  
Gram Positive Bacteria ◽  
Vancomycin Resistant Enterococci ◽  
Infection Models ◽  
Vancomycin Resistant

ABSTRACT In vitro and in vivo activities of DA-7867 were assessed against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and penicillin-resistant Streptococcus pneumoniae. All isolates were inhibited by DA-7867 at ≤0.78 μg/ml, a four-times-lower concentration than that of inhibition by linezolid. For murine infection models, DA-7867 also exhibited greater efficacy than linezolid against all isolates tested.

scholarly journals Persistent Bacteremia fromPseudomonas aeruginosawithIn VitroResistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Louie Mar Gangcuangco ◽  
Patricia Clark ◽  
Cynthia Stewart ◽  
Goran Miljkovic ◽  
Zane K. Saul
Keyword(s):  
Susceptibility Testing ◽  
Resistance Mechanism ◽  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Blood Cultures ◽  
The Novel ◽  
First Case ◽  
Persistent Bacteremia ◽  
Novel Antibiotics

Ceftazidime-avibactam and ceftolozane-tazobactam are new antimicrobials with activity against multidrug-resistantPseudomonas aeruginosa. We present the first case of persistentP.aeruginosabacteremia within vitroresistance to these novel antimicrobials. A 68-year-old man with newly diagnosed follicular lymphoma was admitted to the medical intensive care unit for sepsis and right lower extremity cellulitis. The patient was placed empirically on vancomycin and piperacillin-tazobactam. Blood cultures from Day 1 of hospitalization grewP.aeruginosasusceptible to piperacillin-tazobactam and cefepime identified using VITEK 2 (Biomerieux, Lenexa, KS). Repeat blood cultures from Day 5 grewP.aeruginosaresistant to all cephalosporins, as well as to meropenem by Day 10. Susceptibility testing performed by measuring minimum inhibitory concentration byE-test (Biomerieux, Lenexa, KS) revealed that blood cultures from Day 10 were resistant to ceftazidime-avibactam and ceftolozane-tazobactam. The Verigene Blood Culture-Gram-Negative (BC-GN) microarray-based assay (Nanosphere, Inc., Northbrook, IL) was used to investigate underlying resistance mechanism in theP.aeruginosaisolate but CTX-M, KPC, NDM, VIM, IMP, and OXA gene were not detected. This case report highlights the well-documented phenomenon of antimicrobial resistance development inP.aeruginosaeven during the course of appropriate antibiotic therapy. In the era of increasing multidrug-resistant organisms, routine susceptibility testing ofP. aeruginosato ceftazidime-avibactam and ceftolozane-tazobactam is warranted. Emerging resistance mechanisms to these novel antibiotics need to be further investigated.

scholarly journals A Revised Species Concept for OpportunisticMucorSpecies Reveals Species-Specific Antifungal Susceptibility Profiles

2019 ◽  
Vol 63 (8) ◽  
Author(s):  
Lysett Wagner ◽  
Sybren de Hoog ◽  
Ana Alastruey-Izquierdo ◽  
Kerstin Voigt ◽  
Oliver Kurzai ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Susceptibility Testing ◽  
Species Concept ◽  
Antifungal Susceptibility ◽  
Content Type ◽  
Mucor Indicus ◽  
Species Specific ◽  
Susceptibility Profiles ◽  
High Mics

ABSTRACTRecently, the species concept of opportunisticMucor circinelloidesand its relatives has been revised, resulting in the recognition of its classical formae as independent species and the description of new species. In this study, we used isolates of all clinically relevantMucorspecies and performed susceptibility testing using the EUCAST reference method to identify potential species-specific susceptibility patterns.In vitrosusceptibility profiles of 101 mucoralean strains belonging to the genusMucor(72), the closely related speciesCokeromyces recurvatus(3),Rhizopus(12),Lichtheimia(10), andRhizomucor(4) to six antifungals (amphotericin B, natamycin, terbinafine, isavuconazole, itraconazole, and posaconazole) were determined. The most active drug for all Mucorales was amphotericin B. Antifungal susceptibility profiles of pathogenicMucorspecies were specific for isavuconazole, itraconazole, and posaconazole. The species formerly united inM. circinelloidesshowed clear differences in their antifungal susceptibilities.Cokeromyces recurvatus,Mucor ardhlaengiktus,Mucor lusitanicus(M. circinelloidesf.lusitanicus), andMucor ramosissimusexhibited high MICs to all azoles tested.Mucor indicuspresented high MICs for isavuconazole and posaconazole, andMucor amphibiorumandMucor irregularisshowed high MICs for isavuconazole. MIC values ofMucorspp. for posaconazole, isavuconazole, and itraconazole were high compared to those forRhizopusand the Lichtheimiaceae (LichtheimiaandRhizomucor). Molecular identification combined within vitrosusceptibility testing is recommended forMucorspecies, especially if azoles are applied in treatment.

scholarly journals In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci.

1997 ◽  
Vol 41 (6) ◽  
pp. 1406-1406 ◽  
Author(s):  
P A Evans ◽  
C W Norden ◽  
S Rhoads ◽  
J Deobaldia ◽  
J L Silber
Keyword(s):  
Clinical Isolates ◽  
Vancomycin Resistant Enterococci ◽  
Vancomycin Resistant

scholarly journals Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010

2011 ◽  
Vol 56 (3) ◽  
pp. 1639-1642 ◽  
Author(s):  
Rodrigo E. Mendes ◽  
Leah N. Woosley ◽  
David J. Farrell ◽  
Helio S. Sader ◽  
Ronald N. Jones
Keyword(s):  
Resistance Genes ◽  
Glycopeptide Resistance ◽  
Content Type ◽  
Vancomycin Resistant Enterococci ◽  
Vancomycin Resistant

ABSTRACTOritavancin exhibited potent activity against vancomycin-susceptible (MIC50and MIC90, 0.015/0.03 μg/ml) andvanB-carryingE. faecalisisolates (MIC50and MIC90, 0.015 and 0.015 μg/ml). Higher (16- to 32-fold) MIC50s and MIC90s forvanA-harboringE. faecaliswere noted (MIC50and MIC90, 0.25 and 0.5 μg/ml), although oritavancin inhibited all strains at ≤0.5 μg/ml. Vancomycin-susceptible andvanB-carryingE. faeciumstrains (MIC50and MIC90, ≤0.008 and ≤0.008 μg/ml for both) were very susceptible to oritavancin, as were VanA-producing isolates (MIC50and MIC90, 0.03 and 0.06 μg/ml). Oritavancin exhibited goodin vitropotency against this collection of organisms, including vancomycin-resistant enterococci.

Sign in / Sign up

Export Citation Format

Share Document